ArticlePloS one2016
Entrapment of H1N1 Influenza Virus Derived Conserved Peptides in PLGA Nanoparticles Enhances T Cell Response and Vaccine Efficacy in Pigs.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 76 citations in OpenAlex.
- Efficacy of Purified Borrelial Lipoproteins (PBL) as an oral formulation in reducing transmission of Lyme spirochetes from reservoir hosts tobioRxiv : the preprint server for biology · 2026Article
- Progress in combination vaccines and the co-administration of influenza virus and SARS-CoV-2 vaccines.Frontiers in immunology · 2025Review
- Article
- Biodegradable Polymers in Veterinary Medicine-A Review.Molecules (Basel, Switzerland) · 2024Review
- Article
- Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individuals.Frontiers in immunology · 2024Article
- Swine influenza A virus: challenges and novel vaccine strategies.Frontiers in cellular and infection microbiology · 2024Review
- Influenza vaccine: a review on current scenario and future prospects.Journal, genetic engineering & biotechnology · 2023Review
- Validation of Multi-epitope Peptides Encapsulated in PLGA Nanoparticles Against Influenza A Virus.Pharmaceutical research · 2023Article
- Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines.Journal of nanobiotechnology · 2023Article
- Polymeric Nanoparticles for Inhaled Vaccines.Polymers · 2022Review
- Review
- Nano/microparticle Formulations for Universal Influenza Vaccines.The AAPS journal · 2022Review
- A Single-Dose Intramuscular Nanoparticle Vaccine With or Without Prior Intrauterine Priming Triggers Specific Uterine and Colostral Mucosal Antibodies and Systemic Immunity in Gilts but Not Passive Protection for Suckling Piglets.Frontiers in veterinary science · 2022Article
- Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic.International journal of pharmaceutics · 2021Review
- An Overview of Influenza Viruses and Vaccines.Vaccines · 2021Review
- Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective.Life sciences · 2021Review
- Current and prospective control strategies of influenza A virus in swine.Porcine health management · 2021Review
- Identification and selection of immunodominant B and T cell epitopes for dengue multi-epitope-based vaccine.Medical microbiology and immunology · 2021Review
- Engineered Nanoparticle Applications for Recombinant Influenza Vaccines.Molecular pharmaceutics · 2021Review
Corrections and comments
- Retraction · 2024-07-16Author Unresponsive · Concerns/Issues about Data · Concerns/Issues about Article · Concerns/Issues about Results and/or Conclusions · Falsification/Fabrication of Data · Investigation by Journal/Publisher · Unreliable Data · Unreliable Results and/or Conclusions ·
- Retracted
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pigs are believed to be one of the important sources of emerging human and swine influenza viruses (SwIV). Influenza virus conserved peptides have the potential to elicit cross-protective immune response, but without the help of potent adjuvant and delivery system they are poorly immunogenic. Biodegradable polylactic-co-glycolic acid (PLGA) nanoparticle (PLGA-NP) based vaccine delivery system enhances cross-presentation of antigens by the professional antigen presenting cells. In this study, Norovirus P particle containing SwIV M2e (extracellular domain of the matrix protein 2) chimera and highly conserved two each of H1N1 peptides of pandemic 2009 and classical human influenza viruses were entrapped in PLGA-NPs. Influenza antibody-free pigs were vaccinated with PLGA-NPs peptides cocktail vaccine twice with or without an adjuvant, Mycobacterium vaccae whole cell lysate, intranasally as mist. Vaccinated pigs were challenged with a virulent heterologous zoonotic SwIV H1N1, and one week later euthanized and the lung samples were analyzed for the specific immune response and viral load. Clinically, pigs vaccinated with PLGA-NP peptides vaccine had no fever and flu symptoms, and the replicating challenged SwIV was undetectable in the bronchoalveolar lavage fluid. Immunologically, PLGA-NP peptides vaccination (without adjuvant) significantly increased the frequency of antigen-specific IFNγ secreting CD4 and CD8 T cells response in the lung lymphocytes, despite not boosting the antibody response both at pre- and post-challenge. In summary, our data indicated that nanoparticle-mediated delivery of conserved H1N1 influenza peptides induced the virus specific T cell response in the lungs and reduced the challenged heterologous virus load in the airways of pigs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.